STAAR Surgical Company (STAA) - Net Assets
Based on the latest financial reports, STAAR Surgical Company (STAA) has net assets worth $344.18 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($461.62 Million) and total liabilities ($117.44 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check STAAR Surgical Company tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $344.18 Million |
| % of Total Assets | 74.56% |
| Annual Growth Rate | N/A |
| 5-Year Change | 33.12% |
| 10-Year Change | 808.02% |
| Growth Volatility | 697.69 |
STAAR Surgical Company - Net Assets Trend (1988–2025)
This chart illustrates how STAAR Surgical Company's net assets have evolved over time, based on quarterly financial data. See STAA defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for STAAR Surgical Company (1988–2025)
The table below shows the annual net assets of STAAR Surgical Company from 1988 to 2025. For live valuation and market cap data, see STAA market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $344.18 Million | -13.38% |
| 2024-12-31 | $397.33 Million | +2.95% |
| 2023-12-31 | $385.95 Million | +14.83% |
| 2022-12-31 | $336.11 Million | +29.99% |
| 2021-12-31 | $258.56 Million | +31.10% |
| 2020-12-31 | $197.22 Million | +23.35% |
| 2019-12-31 | $159.88 Million | +20.73% |
| 2018-12-31 | $132.43 Million | +208.43% |
| 2017-12-31 | $42.94 Million | +13.27% |
| 2016-12-31 | $37.91 Million | -2.42% |
| 2015-12-31 | $38.85 Million | +4.71% |
| 2014-12-31 | $37.10 Million | -4.51% |
| 2013-12-31 | $38.85 Million | +22.40% |
| 2012-12-31 | $31.74 Million | +7.75% |
| 2011-12-31 | $29.46 Million | +31.35% |
| 2010-12-31 | $22.43 Million | +6.44% |
| 2009-12-31 | $21.07 Million | +31.47% |
| 2008-12-31 | $16.03 Million | -55.76% |
| 2007-12-31 | $36.23 Million | +14.06% |
| 2006-12-31 | $31.76 Million | -21.32% |
| 2005-12-31 | $40.37 Million | +6.61% |
| 2004-12-31 | $37.86 Million | +6.89% |
| 2003-12-31 | $35.42 Million | +15.57% |
| 2002-12-31 | $30.65 Million | -34.55% |
| 2001-12-31 | $46.83 Million | -20.18% |
| 2000-12-31 | $58.67 Million | +10.28% |
| 1999-12-31 | $53.20 Million | +9.47% |
| 1998-12-31 | $48.60 Million | +8.48% |
| 1997-12-31 | $44.80 Million | +22.40% |
| 1996-12-31 | $36.60 Million | +27.53% |
| 1995-12-31 | $28.70 Million | +30.45% |
| 1994-12-31 | $22.00 Million | +83.33% |
| 1993-12-31 | $12.00 Million | +64.38% |
| 1992-12-31 | $7.30 Million | +69.77% |
| 1991-12-31 | $4.30 Million | +4200.00% |
| 1990-12-31 | $100.00K | +101.25% |
| 1989-12-31 | $-8.00 Million | -100.00% |
| 1988-12-31 | $-4.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to STAAR Surgical Company's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13502400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $498.00K | 0.14% |
| Other Comprehensive Income | $-6.51 Million | -1.89% |
| Other Components | $498.22 Million | 144.75% |
| Total Equity | $344.18 Million | 100.00% |
STAAR Surgical Company Competitors by Market Cap
The table below lists competitors of STAAR Surgical Company ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nanobiotix S.A
PA:NANO
|
$1.39 Billion |
|
China Yuchai International Limited
F:CYD
|
$1.39 Billion |
|
Adecoagro S.A
F:ACD
|
$1.39 Billion |
|
Mota-Engil SGPS S.A
LS:EGL
|
$1.39 Billion |
|
Land and Houses Public Company Limited
BK:LH
|
$1.39 Billion |
|
Crombie Real Estate Investment Trust
TO:CRR-UN
|
$1.39 Billion |
|
Yelp Inc
NYSE:YELP
|
$1.39 Billion |
|
Guangzhou Wondfo Biotech Co Ltd
SHE:300482
|
$1.38 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in STAAR Surgical Company's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 397,335,000 to 344,184,000, a change of -53,151,000 (-13.4%).
- Net loss of 80,448,000 reduced equity.
- Share repurchases of 6,461,000 reduced equity.
- New share issuances of 3,000 increased equity.
- Other comprehensive income increased equity by 520,000.
- Other factors increased equity by 33,235,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-80.45 Million | -23.37% |
| Share Repurchases | $6.46 Million | -1.88% |
| Share Issuances | $3.00K | +0.0% |
| Other Comprehensive Income | $520.00K | +0.15% |
| Other Changes | $33.23 Million | +9.66% |
| Total Change | $- | -13.38% |
Book Value vs Market Value Analysis
This analysis compares STAAR Surgical Company's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.21x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1988-12-31 | $-1.60 | $29.22 | x |
| 1989-12-31 | $-2.90 | $29.22 | x |
| 1990-12-31 | $0.02 | $29.22 | x |
| 1991-12-31 | $0.46 | $29.22 | x |
| 1992-12-31 | $0.72 | $29.22 | x |
| 1993-12-31 | $0.96 | $29.22 | x |
| 1994-12-31 | $2.12 | $29.22 | x |
| 1995-12-31 | $2.10 | $29.22 | x |
| 1996-12-31 | $2.65 | $29.22 | x |
| 1997-12-31 | $3.21 | $29.22 | x |
| 1998-12-31 | $3.38 | $29.22 | x |
| 1999-12-31 | $3.59 | $29.22 | x |
| 2000-12-31 | $3.80 | $29.22 | x |
| 2001-12-31 | $2.73 | $29.22 | x |
| 2002-12-31 | $1.78 | $29.22 | x |
| 2003-12-31 | $1.99 | $29.22 | x |
| 2004-12-31 | $1.93 | $29.22 | x |
| 2005-12-31 | $1.70 | $29.22 | x |
| 2006-12-31 | $1.26 | $29.22 | x |
| 2007-12-31 | $1.29 | $29.22 | x |
| 2008-12-31 | $0.54 | $29.22 | x |
| 2009-12-31 | $0.65 | $29.22 | x |
| 2010-12-31 | $0.64 | $29.22 | x |
| 2011-12-31 | $0.80 | $29.22 | x |
| 2012-12-31 | $0.88 | $29.22 | x |
| 2013-12-31 | $1.01 | $29.22 | x |
| 2014-12-31 | $0.97 | $29.22 | x |
| 2015-12-31 | $0.99 | $29.22 | x |
| 2016-12-31 | $0.94 | $29.22 | x |
| 2017-12-31 | $1.05 | $29.22 | x |
| 2018-12-31 | $2.93 | $29.22 | x |
| 2019-12-31 | $3.41 | $29.22 | x |
| 2020-12-31 | $4.11 | $29.22 | x |
| 2021-12-31 | $5.23 | $29.22 | x |
| 2022-12-31 | $6.81 | $29.22 | x |
| 2023-12-31 | $7.81 | $29.22 | x |
| 2024-12-31 | $8.09 | $29.22 | x |
| 2025-12-31 | $6.94 | $29.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently STAAR Surgical Company utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -23.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -33.60%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 1.34x
- Recent ROE (-23.37%) is below the historical average (72.84%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1988 | 0.00% | -55.88% | 0.42x | 0.00x | $-3.40 Million |
| 1989 | 0.00% | -97.78% | 0.34x | 0.00x | $-3.60 Million |
| 1990 | 3500.00% | 77.78% | 0.42x | 106.00x | $3.49 Million |
| 1991 | -262.79% | -262.79% | 0.46x | 2.19x | $-11.73 Million |
| 1992 | -69.86% | -50.00% | 0.80x | 1.75x | $-5.83 Million |
| 1993 | 20.83% | 12.44% | 1.07x | 1.57x | $1.30 Million |
| 1994 | 37.73% | 30.29% | 0.95x | 1.31x | $6.10 Million |
| 1995 | 26.13% | 21.61% | 0.89x | 1.35x | $4.63 Million |
| 1996 | 18.85% | 16.35% | 0.83x | 1.40x | $3.24 Million |
| 1997 | 16.52% | 17.41% | 0.68x | 1.39x | $2.92 Million |
| 1998 | 5.03% | 4.43% | 0.74x | 1.54x | $-2.37 Million |
| 1999 | 4.17% | 3.73% | 0.69x | 1.62x | $-3.07 Million |
| 2000 | -32.33% | -35.01% | 0.67x | 1.37x | $-24.75 Million |
| 2001 | -31.94% | -29.53% | 0.76x | 1.42x | $-19.48 Million |
| 2002 | -56.16% | -35.56% | 1.07x | 1.48x | $-20.21 Million |
| 2003 | -23.73% | -16.56% | 1.07x | 1.34x | $-11.88 Million |
| 2004 | -29.95% | -21.93% | 0.99x | 1.37x | $-15.12 Million |
| 2005 | -27.68% | -21.78% | 0.97x | 1.31x | $-15.21 Million |
| 2006 | -47.37% | -26.73% | 1.18x | 1.50x | $-18.22 Million |
| 2007 | -44.17% | -26.95% | 1.10x | 1.50x | $-19.62 Million |
| 2008 | -144.72% | -30.97% | 1.42x | 3.28x | $-24.80 Million |
| 2009 | -29.43% | -8.23% | 1.28x | 2.79x | $-8.31 Million |
| 2010 | 0.24% | 0.10% | 1.35x | 1.81x | $-2.19 Million |
| 2011 | 4.58% | 2.15% | 1.28x | 1.66x | $-1.60 Million |
| 2012 | -5.55% | -2.76% | 1.16x | 1.73x | $-4.94 Million |
| 2013 | 1.02% | 0.55% | 1.17x | 1.59x | $-3.49 Million |
| 2014 | -22.62% | -11.19% | 1.27x | 1.59x | $-12.10 Million |
| 2015 | -16.82% | -8.47% | 1.23x | 1.62x | $-10.42 Million |
| 2016 | -32.00% | -14.71% | 1.26x | 1.73x | $-15.92 Million |
| 2017 | -4.98% | -2.36% | 1.33x | 1.58x | $-6.43 Million |
| 2018 | 3.75% | 4.01% | 0.74x | 1.26x | $-8.27 Million |
| 2019 | 8.79% | 9.35% | 0.72x | 1.30x | $-1.94 Million |
| 2020 | 3.00% | 3.62% | 0.64x | 1.31x | $-13.81 Million |
| 2021 | 10.64% | 11.94% | 0.67x | 1.34x | $1.66 Million |
| 2022 | 11.80% | 13.95% | 0.68x | 1.25x | $6.05 Million |
| 2023 | 5.53% | 6.62% | 0.66x | 1.27x | $-17.25 Million |
| 2024 | -5.09% | -6.44% | 0.62x | 1.28x | $-59.94 Million |
| 2025 | -23.37% | -33.60% | 0.52x | 1.34x | $-114.87 Million |
Industry Comparison
This section compares STAAR Surgical Company's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,252,702,307
- Average return on equity (ROE) among peers: -94.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| STAAR Surgical Company (STAA) | $344.18 Million | 0.00% | 0.34x | $1.39 Billion |
| Akoya Biosciences Inc (AKYA) | $7.59 Million | -728.97% | 15.46x | $64.44 Million |
| Align Technology Inc (ALGN) | $-84.67 Million | 0.00% | 0.00x | $12.09 Billion |
| AngioDynamics Inc (ANGO) | $355.71 Million | 3.06% | 0.15x | $447.90 Million |
| AptarGroup Inc (ATR) | $2.71 Billion | 14.48% | 0.94x | $7.66 Billion |
| AtriCure Inc (ATRC) | $483.76 Million | 10.38% | 0.27x | $1.37 Billion |
| Avinger Inc (AVGR) | $-35.69 Million | 0.00% | 0.00x | $1.52 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $18.90 Million | -243.53% | 0.62x | $924.75 Million |
| Avantor Inc (AVTR) | $4.86 Billion | 14.14% | 1.77x | $5.44 Billion |
| Azenta Inc (AZTA) | $121.80 Million | -15.11% | 0.16x | $1.05 Billion |
| Baxter International Inc (BAX) | $4.09 Billion | 0.98% | 1.08x | $9.94 Billion |
About STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorde… Read more